Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 4/20 | 0.41 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | IGF2R | P11717 | 1/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849855 | 0.93 | FGF1 (0.41) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL18412621 | 0.88 | SELE (0.43) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL29632945 | 0.87 | SELE (0.50) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL15948364 | 0.84 | CD209 (0.50) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL15948436 | 0.84 | LGALS8 (0.47) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL15948584 | 0.84 | CD209 (0.49) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL17087678 | 0.84 | LGALS8 (0.55) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL16587625 | 0.83 | SELE (0.48) | SELEFGF1FGF2VEGFAHPSE | |
| SCHEMBL12787207 | 0.82 | MEN1 (0.51) | SELELGALS8IGF2RMAPTAMY1A | |
| SCHEMBL16868390 | 0.82 | MEN1 (0.51) | SELELGALS8IGF2RMAPTAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140369964-A1 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | GLYTECH, INC. (JP) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369964-A1 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | IFNG, IFNAR1, IAPP | SELE 1381/4885FGF1 704/4885FGF2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.